NetworkNewsBreaks – Silo Pharma Inc. (NASDAQ: SI
Post# of 137
(Total Views: 129)
Posted On: 06/23/2023 4:07:54 PM
NetworkNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Working to Deliver Novel Treatment for Chronic Pain Sufferers
Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, recently announced a new research and development agreement to create a time-release ketamine implant to treat fibromyalgia and other chronic pain conditions. Silo intends to leverage its existing partnerships with academic research institutions to help move the novel treatment for chronic pain sufferers through the Food and Drug Administration’s approval process as efficiently as possible. The fibromyalgia market grew to $3.1 billion last year and is expected to continue increasing at a compound annual growth rate of 4% over the next decade. Meanwhile, the larger chronic pain market is projected to exceed $140 billion by 2030, with many chronic pain sufferers in desperate need of a treatment that delivers powerful relief without the serious side effects or risk of addiction that come with opioids.
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, recently announced a new research and development agreement to create a time-release ketamine implant to treat fibromyalgia and other chronic pain conditions. Silo intends to leverage its existing partnerships with academic research institutions to help move the novel treatment for chronic pain sufferers through the Food and Drug Administration’s approval process as efficiently as possible. The fibromyalgia market grew to $3.1 billion last year and is expected to continue increasing at a compound annual growth rate of 4% over the next decade. Meanwhile, the larger chronic pain market is projected to exceed $140 billion by 2030, with many chronic pain sufferers in desperate need of a treatment that delivers powerful relief without the serious side effects or risk of addiction that come with opioids.
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)